Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RAS wild-type + BRAF wild-type
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BRAF positive (1)
BRAF positive (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
RAS wild-type + BRAF wild-type
Colorectal Cancer
RAS wild-type + BRAF wild-type
Colorectal Cancer
cetuximab
Sensitive: C2 – Inclusion Criteria
cetuximab
Sensitive
:
C2
cetuximab
Sensitive: C2 – Inclusion Criteria
cetuximab
Sensitive
:
C2
RAS wild-type + BRAF wild-type
Colorectal Cancer
RAS wild-type + BRAF wild-type
Colorectal Cancer
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
RAS wild-type + BRAF wild-type
Colorectal Cancer
RAS wild-type + BRAF wild-type
Colorectal Cancer
nivolumab + ipilimumab + regorafenib
Sensitive: C3 – Early Trials
nivolumab + ipilimumab + regorafenib
Sensitive
:
C3
nivolumab + ipilimumab + regorafenib
Sensitive: C3 – Early Trials
nivolumab + ipilimumab + regorafenib
Sensitive
:
C3
RAS wild-type + BRAF wild-type
Colorectal Cancer
RAS wild-type + BRAF wild-type
Colorectal Cancer
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
RAS wild-type + BRAF wild-type
Colorectal Cancer
RAS wild-type + BRAF wild-type
Colorectal Cancer
S95026
Sensitive: C3 – Early Trials
S95026
Sensitive
:
C3
S95026
Sensitive: C3 – Early Trials
S95026
Sensitive
:
C3
RAS wild-type + BRAF wild-type
Rectal Cancer
RAS wild-type + BRAF wild-type
Rectal Cancer
panitumumab
Sensitive: C4 – Case Studies
panitumumab
Sensitive
:
C4
panitumumab
Sensitive: C4 – Case Studies
panitumumab
Sensitive
:
C4
RAS wild-type + BRAF wild-type
Colon Cancer
RAS wild-type + BRAF wild-type
Colon Cancer
anlotinib
Sensitive: C4 – Case Studies
anlotinib
Sensitive
:
C4
anlotinib
Sensitive: C4 – Case Studies
anlotinib
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login